Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Apolipoprotein E (Apo-E)

 APOE_PAPAN              Reviewed;         317 AA.
P05770; A0A096P2H8;
01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
07-JUN-2017, sequence version 2.
05-DEC-2018, entry version 101.
RecName: Full=Apolipoprotein E;
Short=Apo-E;
Flags: Precursor;
Name=APOE;
Papio anubis (Olive baboon).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Cercopithecidae; Cercopithecinae; Papio.
NCBI_TaxID=9555;
[1]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=3220472; DOI=10.1016/0888-7543(88)90020-1;
Hixson J.E., Cox L.A., Borenstein S.;
"The baboon apolipoprotein E gene: structure, expression, and linkage
with the gene for apolipoprotein C-1.";
Genomics 2:315-323(1988).
[2]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Liu Y.L., Abraham K.A., Akbar H.A., Ali S.A., Anosike U.A.,
Aqrawi P.A., Arias F.A., Attaway T.A., Awwad R.A., Babu C.B.,
Bandaranaike D.B., Battles P.B., Bell A.B., Beltran B.B.,
Berhane-Mersha D.B., Bess C.B., Bickham C.B., Bolden T.B.,
Carter K.C., Chau D.C., Chavez A.C., Clerc-Blankenburg K.C.,
Coyle M.C., Dao M.D., Davila M.L.D., Davy-Carroll L.D., Denson S.D.,
Dinh H.D., Fernandez S.F., Fernando P.F., Forbes L.F., Francis C.F.,
Francisco L.F., Fu Q.F., Garcia-Iii R.G., Garrett T.G., Gross S.G.,
Gubbala S.G., Hirani K.H., Hogues M.H., Hollins B.H., Jackson L.J.,
Javaid M.J., Jhangiani S.J., Johnson A.J., Johnson B.J., Jones J.J.,
Joshi V.J., Kalu J.K., Khan N.K., Korchina V.K., Kovar C.K.,
Lago L.L., Lara F.L., Le T.-K.L., Lee S.L., Legall-Iii F.L.,
Lemon S.L., Liu J.L., Liu Y.-S.L., Liyanage D.L., Lopez J.L.,
Lorensuhewa L.L., Mata R.M., Mathew T.M., Mercado C.M., Mercado I.M.,
Morales K.M., Morgan M.M., Munidasa M.M., Ngo D.N., Nguyen L.N.,
Nguyen T.N., Nguyen N.N., Obregon M.O., Okwuonu G.O., Ongeri F.O.,
Onwere C.O., Osifeso I.O., Parra A.P., Patil S.P., Perez A.P.,
Perez Y.P., Pham C.P., Pu L.-L.P., Puazo M.P., Quiroz J.Q.,
Rouhana J.R., Ruiz M.R., Ruiz S.-J.R., Saada N.S., Santibanez J.S.,
Scheel M.S., Schneider B.S., Simmons D.S., Sisson I.S., Tang L.-Y.T.,
Thornton R.T., Tisius J.T., Toledanes G.T., Trejos Z.T., Usmani K.U.,
Varghese R.V., Vattathil S.V., Vee V.V., Walker D.W.,
Weissenberger G.W., White C.W., Williams A.W., Woodworth J.W.,
Wright R.W., Zhu Y.Z., Han Y.H., Newsham I.N., Nazareth L.N.,
Worley K.W., Muzny D.M., Rogers J.R., Gibbs R.G.;
"Whole genome assembly of Papio anubis.";
Submitted (MAR-2012) to the EMBL/GenBank/DDBJ databases.
-!- FUNCTION: APOE is an apolipoprotein, a protein associating with
lipid particles, that mainly functions in lipoprotein-mediated
lipid transport between organs via the plasma and interstitial
fluids. APOE is a core component of plasma lipoproteins and is
involved in their production, conversion and clearance.
Apoliproteins are amphipathic molecules that interact both with
lipids of the lipoprotein particle core and the aqueous
environment of the plasma. As such, APOE associates with
chylomicrons, chylomicron remnants, very low density lipoproteins
(VLDL) and intermediate density lipoproteins (IDL) but shows a
preferential binding to high-density lipoproteins (HDL). It also
binds a wide range of cellular receptors including the LDL
receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and
LRP8 and the very low-density lipoprotein receptor/VLDLR that
mediate the cellular uptake of the APOE-containing lipoprotein
particles. Finally, APOE has also a heparin-binding activity and
binds heparan-sulfate proteoglycans on the surface of cells, a
property that supports the capture and the receptor-mediated
uptake of APOE-containing lipoproteins by cells. A main function
of APOE is to mediate lipoprotein clearance through the uptake of
chylomicrons, VLDLs, and HDLs by hepatocytes. APOE is also
involved in the biosynthesis by the liver of VLDLs as well as
their uptake by peripheral tissues ensuring the delivery of
triglycerides and energy storage in muscle, heart and adipose
tissues. By participating to the lipoprotein-mediated distribution
of lipids among tissues, APOE plays a critical role in plasma and
tissues lipid homeostasis. APOE is also involved in two steps of
reverse cholesterol transport, the HDLs-mediated transport of
cholesterol from peripheral tissues to the liver, and thereby
plays an important role in cholesterol homeostasis. First, it is
functionally associated with ABCA1 in the biogenesis of HDLs in
tissues. Second, it is enriched in circulating HDLs and mediates
their uptake by hepatocytes. APOE also plays an important role in
lipid transport in the central nervous system, regulating neuron
survival and sprouting. {ECO:0000250|UniProtKB:P02649}.
-!- SUBUNIT: Homotetramer. {ECO:0000250|UniProtKB:P02649}.
-!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P02649}.
Secreted, extracellular space {ECO:0000250|UniProtKB:P02649}.
Secreted, extracellular space, extracellular matrix
{ECO:0000250|UniProtKB:P02649}. Note=In the plasma, APOE is
associated with chylomicrons, chylomicrons remnants, VLDL, LDL and
HDL lipoproteins. Lipid poor oligomeric APOE is associated with
the extracellular matrix in a calcium- and heparan-sulfate
proteoglycans-dependent manner. Lipidation induces the release
from the extracellular matrix. {ECO:0000250|UniProtKB:P02649}.
-!- PTM: APOE exists as multiple glycosylated and sialylated
glycoforms within cells and in plasma. The extent of glycosylation
and sialylation are tissue and context specific.
{ECO:0000250|UniProtKB:P02649}.
-!- PTM: Glycated in plasma VLDL. {ECO:0000250|UniProtKB:P02649}.
-!- PTM: Phosphorylated by FAM20C in the extracellular medium.
{ECO:0000250|UniProtKB:P02649}.
-!- SIMILARITY: Belongs to the apolipoprotein A1/A4/E family.
{ECO:0000305}.
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
-----------------------------------------------------------------------
EMBL; M29322; AAA35381.1; -; Genomic_DNA.
EMBL; JH682906; -; NOT_ANNOTATED_CDS; Genomic_DNA.
PIR; A28792; A28792.
RefSeq; XP_003918648.1; XM_003918599.2.
ProteinModelPortal; P05770; -.
SMR; P05770; -.
PRIDE; P05770; -.
Ensembl; ENSPANT00000044903; ENSPANP00000042973; ENSPANG00000031383.
GeneID; 101021396; -.
CTD; 348; -.
GeneTree; ENSGT00730000111315; -.
HOVERGEN; HBG010582; -.
OMA; ARLKGWF; -.
OrthoDB; EOG091G0IA5; -.
Proteomes; UP000028761; Unplaced.
GO; GO:0042627; C:chylomicron; IEA:UniProtKB-KW.
GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
GO; GO:0034364; C:high-density lipoprotein particle; IEA:UniProtKB-KW.
GO; GO:0034363; C:intermediate-density lipoprotein particle; IEA:Ensembl.
GO; GO:0034362; C:low-density lipoprotein particle; IEA:Ensembl.
GO; GO:0005886; C:plasma membrane; IEA:GOC.
GO; GO:0043083; C:synaptic cleft; IEA:Ensembl.
GO; GO:0034361; C:very-low-density lipoprotein particle; IEA:UniProtKB-KW.
GO; GO:0001540; F:amyloid-beta binding; ISS:UniProtKB.
GO; GO:0016209; F:antioxidant activity; IEA:Ensembl.
GO; GO:0017127; F:cholesterol transporter activity; IEA:Ensembl.
GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
GO; GO:0071813; F:lipoprotein particle binding; IEA:Ensembl.
GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IEA:Ensembl.
GO; GO:0046911; F:metal chelating activity; IEA:Ensembl.
GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IEA:Ensembl.
GO; GO:0005543; F:phospholipid binding; IEA:Ensembl.
GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
GO; GO:0048156; F:tau protein binding; IEA:Ensembl.
GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; IEA:Ensembl.
GO; GO:0097113; P:AMPA glutamate receptor clustering; IEA:Ensembl.
GO; GO:0042982; P:amyloid precursor protein metabolic process; IEA:Ensembl.
GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl.
GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl.
GO; GO:0006707; P:cholesterol catabolic process; IEA:Ensembl.
GO; GO:0033344; P:cholesterol efflux; IEA:Ensembl.
GO; GO:0042632; P:cholesterol homeostasis; IEA:Ensembl.
GO; GO:0034382; P:chylomicron remnant clearance; IEA:Ensembl.
GO; GO:0055089; P:fatty acid homeostasis; IEA:Ensembl.
GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IEA:Ensembl.
GO; GO:0034380; P:high-density lipoprotein particle assembly; IEA:Ensembl.
GO; GO:0034384; P:high-density lipoprotein particle clearance; IEA:Ensembl.
GO; GO:0034375; P:high-density lipoprotein particle remodeling; IEA:Ensembl.
GO; GO:0010877; P:lipid transport involved in lipid storage; IEA:Ensembl.
GO; GO:0042158; P:lipoprotein biosynthetic process; IEA:Ensembl.
GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl.
GO; GO:0035641; P:locomotory exploration behavior; IEA:Ensembl.
GO; GO:0015909; P:long-chain fatty acid transport; IEA:Ensembl.
GO; GO:0007616; P:long-term memory; IEA:Ensembl.
GO; GO:0034374; P:low-density lipoprotein particle remodeling; IEA:Ensembl.
GO; GO:0051651; P:maintenance of location in cell; IEA:Ensembl.
GO; GO:1902430; P:negative regulation of amyloid-beta formation; IEA:Ensembl.
GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IEA:Ensembl.
GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
GO; GO:0045541; P:negative regulation of cholesterol biosynthetic process; IEA:Ensembl.
GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl.
GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; IEA:Ensembl.
GO; GO:0043407; P:negative regulation of MAP kinase activity; IEA:Ensembl.
GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
GO; GO:0010544; P:negative regulation of platelet activation; IEA:Ensembl.
GO; GO:1901630; P:negative regulation of presynaptic membrane organization; IEA:Ensembl.
GO; GO:0090209; P:negative regulation of triglyceride metabolic process; IEA:Ensembl.
GO; GO:0007263; P:nitric oxide mediated signal transduction; IEA:Ensembl.
GO; GO:0097114; P:NMDA glutamate receptor clustering; IEA:Ensembl.
GO; GO:0033700; P:phospholipid efflux; IEA:Ensembl.
GO; GO:0044794; P:positive regulation by host of viral process; IEA:Ensembl.
GO; GO:0010875; P:positive regulation of cholesterol efflux; IEA:Ensembl.
GO; GO:0010873; P:positive regulation of cholesterol esterification; IEA:Ensembl.
GO; GO:0060999; P:positive regulation of dendritic spine development; IEA:Ensembl.
GO; GO:1902952; P:positive regulation of dendritic spine maintenance; IEA:Ensembl.
GO; GO:0045807; P:positive regulation of endocytosis; IEA:Ensembl.
GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
GO; GO:1905855; P:positive regulation of heparan sulfate binding; IEA:Ensembl.
GO; GO:1905860; P:positive regulation of heparan sulfate proteoglycan binding; IEA:Ensembl.
GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IEA:Ensembl.
GO; GO:1903002; P:positive regulation of lipid transport across blood-brain barrier; IEA:Ensembl.
GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; IEA:Ensembl.
GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IEA:Ensembl.
GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IEA:Ensembl.
GO; GO:1902995; P:positive regulation of phospholipid efflux; IEA:Ensembl.
GO; GO:1901628; P:positive regulation of postsynaptic membrane organization; IEA:Ensembl.
GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
GO; GO:0017038; P:protein import; IEA:Ensembl.
GO; GO:0006898; P:receptor-mediated endocytosis; IEA:Ensembl.
GO; GO:1905906; P:regulation of amyloid fibril formation; IEA:Ensembl.
GO; GO:1900221; P:regulation of amyloid-beta clearance; IEA:Ensembl.
GO; GO:0042981; P:regulation of apoptotic process; IEA:Ensembl.
GO; GO:2000822; P:regulation of behavioral fear response; IEA:Ensembl.
GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IEA:Ensembl.
GO; GO:1905890; P:regulation of cellular response to very-low-density lipoprotein particle stimulus; IEA:Ensembl.
GO; GO:0045088; P:regulation of innate immune response; IEA:Ensembl.
GO; GO:0061136; P:regulation of proteasomal protein catabolic process; IEA:Ensembl.
GO; GO:0032462; P:regulation of protein homooligomerization; IEA:Ensembl.
GO; GO:0061771; P:response to caloric restriction; IEA:Ensembl.
GO; GO:0002021; P:response to dietary excess; IEA:Ensembl.
GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
GO; GO:0043691; P:reverse cholesterol transport; IEA:Ensembl.
GO; GO:0070328; P:triglyceride homeostasis; IEA:Ensembl.
GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl.
GO; GO:0042311; P:vasodilation; IEA:Ensembl.
GO; GO:0034447; P:very-low-density lipoprotein particle clearance; IEA:Ensembl.
GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IEA:Ensembl.
GO; GO:0019068; P:virion assembly; IEA:Ensembl.
InterPro; IPR000074; ApoA_E.
Pfam; PF01442; Apolipoprotein; 1.
3: Inferred from homology;
Chylomicron; Complete proteome; Extracellular matrix; Glycoprotein;
HDL; Heparin-binding; Lipid transport; Lipid-binding; Oxidation;
Phosphoprotein; Reference proteome; Repeat; Secreted; Signal;
Transport; VLDL.
SIGNAL 1 18 {ECO:0000250|UniProtKB:P02649}.
CHAIN 19 317 Apolipoprotein E.
/FTId=PRO_0000001992.
REPEAT 80 101 1.
REPEAT 102 123 2.
REPEAT 124 145 3.
REPEAT 146 167 4.
REPEAT 168 189 5.
REPEAT 190 211 6.
REPEAT 212 233 7.
REPEAT 234 255 8.
REGION 80 255 8 X 22 AA approximate tandem repeats.
REGION 158 168 LDL and other lipoprotein receptors
binding. {ECO:0000250|UniProtKB:P02649}.
REGION 162 165 Heparin-binding.
{ECO:0000250|UniProtKB:P02649}.
REGION 210 290 Lipid-binding and lipoprotein
association.
{ECO:0000250|UniProtKB:P02649}.
REGION 229 236 Heparin-binding.
{ECO:0000250|UniProtKB:P02649}.
REGION 266 317 Homooligomerization.
{ECO:0000250|UniProtKB:P02649}.
REGION 278 290 Specificity for association with VLDL.
{ECO:0000250|UniProtKB:P02649}.
MOD_RES 143 143 Methionine sulfoxide.
{ECO:0000250|UniProtKB:P08226}.
MOD_RES 147 147 Phosphoserine.
{ECO:0000250|UniProtKB:P02649}.
CONFLICT 31 32 EL -> DV (in Ref. 1; AAA35381).
{ECO:0000305}.
SEQUENCE 317 AA; 36021 MW; 3DCF7AEA1F22E48E CRC64;
MKVLWAALLV TFLAGCQAKV EQPVEPETEP ELRQQAEWQS GQPWELALGR FWDYLRWVQT
LSEQVQEELL SPQVTQELTT LMDETMKELK AYKSELEEQL SPVAEETRAR LSKELQAAQA
RLGADMEDVR SRLVQYRSEV QAMLGQSTEE LRARLASHLR KLRKRLLRDA DDLQKRLAVY
QAGAREGAER GVSAIRERLG PLVEQGRVRA ATVGSLASQP LQERAQALGE RLRARMEEMG
SRTRDRLDEV KEQVAEVRAK LEEQAQQISL QAEAFQARLK SWFEPLVEDM QRQWAGLVEK
VQAAVGASTA PVPSDNH


Related products :

Catalog number Product name Quantity
20-272-192023 Apolipoprotein J - Mouse monoclonal [Hs - 3] to Apolipoprotein J; Complement-associated protein SP-40.40; Complement cytolysis inhibitor; CLI; NA1_NA2; Apolipoprotein J; Apo-J; Testosterone-repressed 0.05 mg
U1890m CLIA kit Apoc3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Mouse,Mus musculus 96T
U1890r CLIA Apoc3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Rat,Rattus norvegicus 96T
E1890m ELISA Apoc3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Mouse,Mus musculus 96T
U1890m CLIA Apoc3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Mouse,Mus musculus 96T
U1890b CLIA APOC3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Bos taurus,Bovine 96T
E0604h ELISA APOA1,Apo-AI,ApoA-I,Apolipoprotein A1,Apolipoprotein A-I,Homo sapiens,Human 96T
E1890r ELISA Apoc3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Rat,Rattus norvegicus 96T
E1890m ELISA kit Apoc3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Mouse,Mus musculus 96T
Y051160 Anti-human Apolipoprotein Apolipoprotein-H (β2-Glycoprotein-I )Peroxidase Conjugated IgG Antibody 100μg
E0252m ELISA Apoc1,Apoc1b,Apo-CIB,ApoC-IB,Apolipoprotein C1,Apolipoprotein C-I,Mouse,Mus musculus 96T
E1890b ELISA APOC3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Bos taurus,Bovine 96T
U0604h CLIA APOA1,Apo-AI,ApoA-I,Apolipoprotein A1,Apolipoprotein A-I,Homo sapiens,Human 96T
E0604Rb ELISA APOA1,Apo-AI,ApoA-I,Apolipoprotein A1,Apolipoprotein A-I,Oryctolagus cuniculus,Rabbit 96T
U1890b CLIA kit APOC3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Bos taurus,Bovine 96T
E0604Rb ELISA kit APOA1,Apo-AI,ApoA-I,Apolipoprotein A1,Apolipoprotein A-I,Oryctolagus cuniculus,Rabbit 96T
E1890b ELISA kit APOC3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Bos taurus,Bovine 96T
E0252m ELISA kit Apoc1,Apoc1b,Apo-CIB,ApoC-IB,Apolipoprotein C1,Apolipoprotein C-I,Mouse,Mus musculus 96T
E0604h ELISA kit APOA1,Apo-AI,ApoA-I,Apolipoprotein A1,Apolipoprotein A-I,Homo sapiens,Human 96T
U1890r CLIA kit Apoc3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Rat,Rattus norvegicus 96T
Y051160 Anti-human Apolipoprotein Apolipoprotein-H β2-Glycoprotein-I Peroxidase Conjugated IgG antibody 250ug
U0252m CLIA Apoc1,Apoc1b,Apo-CIB,ApoC-IB,Apolipoprotein C1,Apolipoprotein C-I,Mouse,Mus musculus 96T
E1890r ELISA kit Apoc3,Apo-CIII,ApoC-III,Apolipoprotein C3,Apolipoprotein C-III,Rat,Rattus norvegicus 96T
U0604Rb CLIA APOA1,Apo-AI,ApoA-I,Apolipoprotein A1,Apolipoprotein A-I,Oryctolagus cuniculus,Rabbit 96T
E0604m ELISA Apoa1,Apo-AI,ApoA-I,Apolipoprotein A1,Apolipoprotein A-I,Mouse,Mus musculus 96T


https://antibody-antibodies.com/ | https://gentaur.com/ | https://gen-script.com/ | https://diagenox.com/ | https://clonagen.com/ | http://gentaursearch.com/ | http://gentaurpub.com/ | https://gentaur-online.com/ | http://anti-anti-pdf.com/ | http://gentaur-worldwide.com/

 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur | Gentaur





GENTAUR Ltd.
Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
IBAN FR76 3000 4001 8700 0100 9225 310
france@gentaur.com | Gentaur | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: +49 0241 40 08 90 86, +49 0241 95 78 94 78, +49 0241 40 08 90 86
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur | Gentaur